Watch Point Trust Co Sells 4,315 Shares of Merck & Co., Inc. (NYSE:MRK)

Watch Point Trust Co lessened its holdings in Merck & Co., Inc. (NYSE:MRK) by 32.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 9,002 shares of the company’s stock after selling 4,315 shares during the period. Watch Point Trust Co’s holdings in Merck & Co., Inc. were worth $758,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Titan Capital Management LLC CA purchased a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $25,000. LFA Lugano Financial Advisors SA grew its holdings in Merck & Co., Inc. by 250.0% during the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after buying an additional 225 shares in the last quarter. JJJ Advisors Inc. bought a new stake in Merck & Co., Inc. during the second quarter worth $27,000. Cumberland Partners Ltd bought a new stake in Merck & Co., Inc. during the second quarter worth $40,000. Finally, Fusion Family Wealth LLC grew its holdings in Merck & Co., Inc. by 268.2% during the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after buying an additional 354 shares in the last quarter. 74.95% of the stock is owned by institutional investors and hedge funds.

Several research analysts have weighed in on the company. Argus boosted their price objective on Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. ValuEngine cut Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Mizuho boosted their price objective on Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Leerink Swann assumed coverage on Merck & Co., Inc. in a research report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 price objective on the stock. Finally, Bank of America assumed coverage on Merck & Co., Inc. in a research report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company. Merck & Co., Inc. currently has an average rating of “Buy” and an average target price of $95.13.

Shares of NYSE MRK traded up $0.71 during trading on Friday, reaching $83.59. 6,053,527 shares of the stock traded hands, compared to its average volume of 10,105,755. Merck & Co., Inc. has a 52-week low of $70.89 and a 52-week high of $87.35. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92. The company has a 50-day moving average of $84.01 and a 200-day moving average of $82.77. The stock has a market capitalization of $212.31 billion, a P/E ratio of 19.26, a price-to-earnings-growth ratio of 1.80 and a beta of 0.54.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, beating analysts’ consensus estimates of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The firm had revenue of $12.40 billion for the quarter, compared to analysts’ expectations of $11.59 billion. During the same quarter in the prior year, the firm earned $1.19 EPS. The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. Analysts expect that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: What is the G-20?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.